May 17, 2020

Softbank Group leads the $93mn investment in Petuum Inc

Softbank Group
Catherine Sturman
2 min
Supply chain payments company, Tradeshift, has raised $250mn in a new funding round, increasing the valuation of the business to $1.1bn.
Softbank has been behind the substantial growth of Petuum Inc, closing $93 million in Series B funding, with participation from previous investorAdvante...

Softbank has been behind the substantial growth of Petuum Inc, closing $93 million in Series B funding, with participation from previous investor Advantech Capital.

Implementing machine learning applications to be deployed at scale, transforming businesses and supporting long-term growth, Petuum’s flexible operating system and virtualisation interface will enable users to build any type of machine learning or deep learning application, which can then be utilised on a wide range of enterprise hardware – including datacentres and IoT – where the management of applications and hardware are then able to come from a single terminal.

"We are firm believers in the value that AI can bring to a broad range of industries," said SoftBank Managing Partner Deep Nishar. "Petuum's work will finally help to unlock that value."

Related stories

One particular area of interest for the company is the digitisation of the healthcare industry and the need for software which can support the ongoing delivery of patient-centric care through the use of advanced data analytics. The use of Electronic Medical Records is becoming an increased area of focus and how such systems can be made more efficient across the board.

With this in mind, tech giants such as Apple and Amazon are continuing to look at the long-term growth of the healthcare industry and use of AI, alongside the growing use of health wearables and use of VR through the delivery of personalised care. This is also in alignment with a growing consumer healthcare market.

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article